Rx-360 elects new board members

They will stand for a three-year term that expires in 2014

The Rx-360 international consortium of pharmaceutical and biotechnology companies, which was formed in 2009 to support an industry-wide commitment to ensuring patient safety by enhancing quality and authenticity throughout the supply chain, has elected new members to its board of directors.

The following individuals have been elected to a three-year term that expires at the end of 2014:

  • Janice Berman (Takeda)
  • Heike Falkenhagen (Boehringer Ingelheim)
  • Hubertus Folttmann (BASF)
  • Jaspret Gill (Baxter)
  • Brian Johnson (Pfizer)
  • Patrica Latzo (Mylan)
  • Elizabeth Pileggi (Teva)
  • Swroop Sahota (Merck)
  • Melissa Seymour (Biogen Idec)

You may also like

Regulatory

Rx-360 Consortium releases GMP Audit Manual

Document for pharma companies, contract manufacturers and laboratories focuses on data governance and data integrity
Regulatory

Rx-360 creates Asia Working Group

The working group will focus its attention on identifying and mitigating root causes of quality problems and supply chain security
Ingredients

Ebola West Africa outbreak could affect pharma ingredients supply chain

The largest exports from Liberia are palm oil and palm kernel oil, a key building block in many raw materials
Regulatory

Rx-360 sets up Traceability Data Exchange Architecture Work Group

Will develop conceptual models for information exchange to comply with global regulations
Regulatory

Rx-360 implements pilots for new audit programme options

An important step in continuous improvement of supply chain security programmes
Ingredients

EMA gives more clarification on new EU regs for importing APIs

A new Q&A document (Version 3) has been published by the European Medicines Agency
Manufacturing

InformEx USA conference programme to provide on-point education for chemical industry

The latest trends and best business practices for the speciality, fine and custom chemicals marketplace
Subscribe now